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Abstract
Msb2 is a sensor protein in the plasma membrane of fungi. In the human fungal pathogen C. albicans Msb2 signals via the
Cek1 MAP kinase pathway to maintain cell wall integrity and allow filamentous growth. Msb2 doubly epitope-tagged in its
large extracellular and small cytoplasmic domain was efficiently cleaved during liquid and surface growth and the
extracellular domain was almost quantitatively released into the growth medium. Msb2 cleavage was independent of
proteases Sap9, Sap10 and Kex2. Secreted Msb2 was highly O-glycosylated by protein mannosyltransferases including Pmt1
resulting in an apparent molecular mass of .400 kDa. Deletion analyses revealed that the transmembrane region is
required for Msb2 function, while the large N-terminal and the small cytoplasmic region function to downregulate Msb2
signaling or, respectively, allow its induction by tunicamycin. Purified extracellular Msb2 domain protected fungal and
bacterial cells effectively from antimicrobial peptides (AMPs) histatin-5 and LL-37. AMP inactivation was not due to
degradation but depended on the quantity and length of the Msb2 glycofragment. C. albicans msb2 mutants were
supersensitive to LL-37 but not histatin-5, suggesting that secreted rather than cell-associated Msb2 determines AMP
protection. Thus, in addition to its sensor function Msb2 has a second activity because shedding of its glycofragment
generates AMP quorum resistance.
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Introduction
Crosstalk between pathogens and the human host determines
the outcome of microbial colonization and disease [1]. Pathogen-
host communication occurs between cells and secreted proteins of
both organisms. Surface structures of the important human fungal
pathogen Candida albicans bind to dectin receptors on immune cells
and trigger responses inhibiting fungal proliferation including the
production of antimicrobial peptides (AMPs) and reactive oxygen
species (ROS) (for a review, see [2,3]. In addition, binding to
immunoglobulins and complement factors by the fungal pathogen
facilitate its phagocytosis and killing (for a review, see [4]).
Conversely, C. albicans partially overcomes host defenses by
secreting hydrolytic enzymes and proteins that block the
complement system (for a review, see [4,5]). Furthermore, by
switching its growth from a yeast to a hyphal growth form C.
albicans is able to evade immune cells and to penetrate into host
niches less accessible to the immune system.
Survival of fungal pathogens in the human host requires that
their cell surfaces are intact. Defects in the cell wall of C. albicans
that occur under immune attack or by treatment with antifungals
are sensed and activate compensatory activities [6]. Reduced
glucan content leads to the activation of the protein kinase C
(PKC) pathway that includes the Mkc1 MAPK module, which
activates the glucan synthase activity and stimulates the transcrip-
tion of genes involved in glucan and chitin biosynthesis [7,8]. In
addition, defective N- or O-glycosylation activates the Cek1
MAPK module and recent results indicate that PMT genes
encoding protein-O-mannosyltransferases are downstream regula-
tory targets [9,10]. Sensing through this pathway is accomplished
by the Msb2 and Sho1 cytoplasmic membrane proteins, which
signal via the Cdc42 GTPase to Cek1. Intact N-glycosylation is
detected by Msb2 and represses PMT1 transcription, while
defective N-glycosylation induces Cek1 phosphorylation and de-
represses PMT1 transcription [9,10]. In a different mode of
regulation, defective Pmt1-type O-glycosylation is sensed by Msb2,
activates Cek1 and induces PMT2 and PMT4 expression.
Induction of PMT2/PMT4 genes by inhibition of Pmt1 and
damage of b1,3-glucan also requires Msb2 and Cek1 suggesting
that cell wall damage is reported to Cek1 via Msb2 [10]. This
function of Msb2 is supported by its associated partner membrane
protein Sho1 [9]. Defects in either Mkc1 or Cek1 pathways lead to
defective hypha formation on some semi-solid media, supersensi-
tivity against antifungals and other stressors and reduce the
virulence of C. albicans [9,11,12].
Msb2 is a type I membrane protein containing a single
transmembrane region that separates a large extracellular from a
small cytoplasmic domain; this structure is conserved in several
fungal species [13–16]. Msb2 in the yeast Saccharomyces cerevisiae has
been shown to be continuously cleaved by the Yps1 yapsin
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medium [17]. This property, coupled with the high level of N-
and O-glycosylation of the extracellular domain has led to the
concept that fungal Msb2 proteins represent functional analogs of
the mammalian MUC1/2 signaling mucins, which by proteolytic
cleavage generate highly hydrated mucous glycoprotein layers
around cells and at the same time confer transcriptional
regulation by the cleaved cytoplasmic domain [18]. In fungi,
intertwining of Msb2 hydrated glycostructures with cell wall
components may be related to the sensing function of Msb2.
Cleavage of the ScMsb2 cytoplasmic domain has not been
reported and its presence may be required for Cdc42 binding,
which is an essential upstream element of the Kss1 MAPK
pathway [13]. Here we report that the glycosylated extracellular
domain of C. albicans Msb2 is released into the growth medium in
considerable amounts and we show that the shed protein has the
function to protect against AMPs produced by the host. In
humans, the most prominent AMPs exhibiting strong antimicro-
bial and immunostimulatory activities are the histatins, which are
produced by salivary glands and secreted into saliva and the
cathelicidins and defensins, which are produced by neutrophils
and macrophages (for a review, see [19–21]). The human
cathelicidin LL-37 occurs on mucosal surfaces at a concentration
of 2–5 mg/ml but its concentration rises to 1.5 mg/ml in acute
inflammation [22]. Histatin-5 and LL-37 are cationic AMPs that
damage the cytoplasmic membranes of C. albicans [23–25] and
histatin-5 also attacks intracellular targets [26]. The combined
findings of this study suggest that shed Msb2 is a glycoprotein that
effectively protects C. albicans against killing by AMPs LL-37 and
histatin-5, allowing C. albicans to evade immune reactions and to
allow its persistence as a commensal.
Results
Construction and activity of epitope-tagged Msb2
To immunologically detect Msb2 we constructed a strain
producing a variant Msb2 protein carrying an HA-epitope within
the large extracellular domain and in addition a V5-epitope in the
middle of the short cytoplasmic domain (Figure 1 A). MSB2 was
expressed either under the control of the constitutive ACT1
promoter when plasmid pES11a was integrated in the LEU2 locus
(strain ESCa3) or by the authentic MSB2 promoter when pES11a
was integrated in the partially deleted msb2D1 allele of strain
FCCa28 (strain ESCa10). The msb2D1 allele encoding 406 N-
terminal residues of Msb2 was found to be completely non-
functional in all phenotypic assays (see below) and it was fully
complemented in transformants containing pES11a integrated in
both genomic loci; complementation efficiencies were equal
between transformants carrying singly HA-tagged or doubly
HA-V5-tagged Msb2 versions. Thus, while several msb2D1 mutant
strains were as supersensitive to caspofungin and tunicamycin as
the pmt4 control strain [10] complementation by the epitope-
tagged versions of Msb2 restored normal resistance (Figure 1 B).
While tunicamycin-supersensitivity indicates that msb2D1 mutants
require intact N-glycosylation for growth, O-mannosylation by
Pmt1 appears not relevant since mutants grew normally in the
presence of the Pmt1 inhibitor. The tagged versions of Msb2 were
also fully active to reverse the hyphal growth defects of the msb2D1
mutants [9] (Figure 1 C).
In addition, we constructed plasmid pES11c, which encodes the
HA-tagged Msb2 variant carrying the V5 epitope at its C-terminal
end (allele MSB2
HA-V5 end). The phenotypic results for pES11a-
and pES11c-transformants were identical (data not shown).
Secretion and processing of Msb2
Release of a Msb2 subfragment into the growth medium has
been observed in S. cerevisiae and other fungi [13–16]. When we
examined cells and growth medium of C. albicans transformants
producing tagged Msb2 by immunoblotting we discovered that the
majority of HA-carrying Msb2 was present in the medium and
migrated as a diffuse band of .460 kDa (Figure 2 A). No
significant difference regarding the amount of immunoreactive
protein was detected in strains either transcribing MSB2 from the
ACT1 or MSB2 promoters (compare lanes 3 and 5) suggesting that
both promoters are of comparable strength. As expected, the
tagged ER-membrane protein Pmt1
HA was associated only with
cells (lane 2). In contrast to HA immunodetection the V5-tagged
Msb2 protein was found exclusively in association with cells and
not in the medium, similar to the Pmt2
V5 control protein (Figure 2
B). The V5-tagged Msb2 protein migrated as a doublet of about
15 kDa and thus corresponded in size to the cytoplasmic domain
of Msb2. Thus, it appears that during growth in liquid culture the
Msb2 full-length protein is mostly cleaved proteolytically into the
large extracellular (HA-tagged) and the small cytoplasmic (V5-
tagged) subfragments. Importantly, release of the Msb2
HA
fragment was almost quantitative during growth in complex
YPD growth medium and was not altered significantly in YEPG
medium containing galactose as in S. cerevisiae [17] or during hypha
formation in YP medium containing 10% serum (data not shown).
The released extracellular fragment or Msb2 will now be referred
to as Msb2*.
To examine if Msb2* secretion would also occur during growth
on a semisolid agar surface we used a double sandwich system
consisting of a PVDF membrane used for immunoblotting topped
by a membrane filter precluding the passage of cells, which were
both placed on YPD agar (Figure 2 C, a). Cells grew on the
membrane filter (Figure 2 C, b) and immunoanalysis of the PVDF
filter detected HA-proteins only released from cells producing
Msb2* (Figure 2 C, c 3, 4) but not from cell producing tagged
Pmt1
HA protein. This result indicates that the extracellular Msb2
fragment is also detected in surface growth of C. albicans.
Considering the possibility that Msb2 is cleaved immediately
upstream of the transmembrane region it was expected that Msb2*
has an approximate molecular mass of 131 kDa but the
heterogeneity and apparent molecular mass in immunoblotting
(Figure 2 A) suggested extensive glycosylation. To estimate its
molecular mass more accurately we carried out fractionation of
culture fluid containing Msb2* by gel filtration, using a column
previously calibrated with standard proteins (Figure 2 D, a, b).
Fractions eluted from the column were examined by immunode-
tection and yielded a major peak from 468–614 kDa (Figure 2 D,
c) in agreement with the above immunoblotting results. A minor
peak in the void volume, presumably representing aggregated
Author Summary
Microbial pathogens are attacked by antimicrobial pep-
tides (AMPs) produced by the human host. AMPs kill
pathogens and recruit immune cells to the site of
infection. In defense, the human fungal pathogen Candida
albicans continuously cleaves and secretes a glycoprotein
fragment of the surface protein Msb2, which protects
against AMPs. The results suggest that shed Msb2 allows
fungal colonies to persist and avoid inflammatory respons-
es caused by AMPs. Msb2 shedding and its additional role
in stabilizing the fungal cell wall may be considered as
novel diagnostic tools and targets for antifungal action.
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suggested that glycosylation contributed equally to the mass of
Msb2* as its protein content we attempted to clarify the type of
protein glycosylation. Extensive treatment of the growth medium
(and of purified Msb2*, see below) with PNGase F did not result in
a significant alteration of its apparent molecular mass (data not
shown), while b-elimination led to a mass reduction to about
300 kDa (Figure 2 E, a) indicating that Msb2* is significantly O-
but not N-glycosylated. On the other hand, complete chemical
deglycosylation by trifluoromethanesulfonic acid (TFMS) reduced
the mass of Msb2* to about 117–130 kDa (Figure 2 E, b)
consistent with the proteolytic cleavage of the Msb2 precursor
protein immediately upstream of the transmembrane region
(expected molecular mass of unmodified 1291 residue fragment
is 130 kDa). It is yet unclear if the different deglycosylation results
obtained for b-elimination and TFMS treatments is due to residual
O-glycosylation not removable by b-elimination, by residual N-
glycosylation, which is not removed by PNGase F or by yet
unknown modifications. However, because clear evidence for O-
glycosylation of secreted Msb2 was obtained we produced epitope-
tagged Msb2 in C. albicans mutants lacking each of the 5 isoforms
of protein-O-mannosyltransferases. Immunoanalysis of secreted
Msb2* showed faster electrophoretic mobility in the pmt1 mutant,
while in the pmt4, pmt5 and pmt6 homozygous mutants no
difference to the control strain was detected (Figure 2 E, c). We
conclude that Pmt1 is at least partially involved in Msb2 O-
glycosylation, although the contribution of Pmt2 (only testable in a
heterozygous PMT2/pmt2 strain since it is essential for growth
[27]) cannot be excluded. Compensatory upregulation of other
Pmt isoforms in a pmt1 mutant [10,28] may also account for
remaining Msb2 O-glycosylation, which showed a very broad
mobility distribution corresponding to apparent molecular masses
from 240–480 kDa.
It has been reported that in S. cerevisiae the yapsin-type protease
Yps1 is responsible for cleavage and secretion of Msb2 [17]. In C.
albicans the closest homolog to Yps1 is Sap9 (21.9% identity), while
Sap10 is also structurally similar because it is GPI-anchored in the
cytoplasmic membrane [29]. When we expressed the tagged
MSB2
HA-V5 allele in the sap9 mutant (ESCa33), the sap10 mutant
(ESCa34) or the sap9 sap10 double mutant (ESCa35) we did not
observe any difference in amounts and molecular masses of Msb2*
(data not shown). We also observed normal secretion of Msb2 in a
Figure 1. Structure and activity of epitope-tagged Msb2. A. Structure of MSB2 alleles encoding Msb2 variants. The MSB2 coding region with
sequences encoding the signal sequence (SS), the transmembrane region (TM), HA- /V5-epitopes and relevant restriction sites used for the
construction of MSB2 variant alleles are shown. B. Tagged MSB2 alleles confer inhibitor resistance. Sensitivity of strains to caspofungin (125 ng/ml),
tunicamycin (2 mg/ml) and Pmt1 inhibitor (12 mM) was tested by a drop dilution test. C. Tagged MSB2 alleles reconstitute formation of hyphae on
YPM agar. Colonies of strains were photographed following growth for 2 d at 37uC. Strains CAF2-1 (wt), FCCa27 (msb2D1 URA3) and FCCa28 (msb2D1
ura3) were compared to FCCa28 transformants. Transformants contained empty plasmid pDS1044-1 (ESCa7; msb2D1[empty]), pES10 (ESCa8;
msb2D1[ACT1p-MSB2
HA]) or pES11a (ESCa3; msb2D1[ACT1p-MSB2
HA-V5]) integrated in the LEU2 locus. The tagged MSB2 allele was also placed under
transcriptional control of the authentic MSB2 promoter by directing integration of HpaI-cut pES11a into the msb2D1 allele of FCCa28 (ESCa10;
msb2D1 [MSB2p-MSB2
HA-V5)]). Strain CAP4-2164 (pmt4) was used as a supersensitive control strain [27].
doi:10.1371/journal.ppat.1002501.g001
Msb2 Shedding
PLoS Pathogens | www.plospathogens.org 3 February 2012 | Volume 8 | Issue 2 | e1002501Figure 2. Secretion and processing of Msb2. C. albicans strains grown in YPD medium to OD600=6, centrifuged and cell extracts (50 mg protein
derived from cells in 90 ml of medium) or medium (20 ml) were analyzed for epitope-tagged Msb2 protein. A. Immunoblot to detect HA-tagged Msb2.
Proteins were separated by a 8% SDS-PAGE gel and immunoblots were reacted with rat anti-HA antibody. Strains tested included ESCa8 (ACT1p-
MSB2
HA; lanes 3 and 8), ESCa3 (ACT1p-MSB2
HA-V5; lanes 4 and 9), ESCa9 (MSB2p-MSB2
HA; lanes 5 and 10) and ESCa10 (MSB2p-MSB2
HA-V5; lanes 6 and
11). Strains CAF2-1 (wt) and CIS23 (PMT1
HA) were used as negative and positive control strains, respectively. The migration of HA-tagged Msb2 and
Pmt1 are indicated by the arrow and triangle, respectively. B. Immunoblot to detect V5-tagged Msb2. Proteins were separated by a 4–20% gradient
Msb2 Shedding
PLoS Pathogens | www.plospathogens.org 4 February 2012 | Volume 8 | Issue 2 | e1002501mutant (ESCa36) lacking the furin-type and Golgi-resident Kex2
serine endoproteinase, which in S. cerevisiae is required for cleavage
and shedding of the Flo11 protein [30]. Furthermore, we
repeatedly added high concentrations (15 mg/ml) of the aspartyl
protease inhibitor pepstatin, of the metalloprotease inhibitor
amastatin (15 mg/ml) or of a commercial mix of inhibitors for
serine- and cysteine proteases (complete mini tablets; Roche) to
growing cultures of ESCa3 but we did not find any effect on
Msb2* release (data not shown). We conclude that the processing
mechanism of Msb2 in C. albicans requires an as yet unidentified
protease and that Sap9, Sap10 and Kex2 proteases are not
involved.
Structure-function relationship of Msb2
We constructed several C. albicans strains producing deleted
Msb2 variants under the control of the ACT1 promoter in a msb2
mutant background and tested Msb2-dependent phenotypes
including secretion of Msb2, hypha formation and resistance to
caspofungin; furthermore, the ability of variants to activate the
Cek1 MAP kinase was examined. The results are summarized in
Figure 3 A and presented in Figure 3 B and Figure S1.
Two major deletion variants either lacking 449 residues of the
extracellular domain (Msb2-DN) or lacking the complete cyto-
plasmic tail of 103 residues (Msb2-DC) were fully able to
complement all msb2 mutant phenotypes. In contrast, strains only
SDS-PAGE gel and immunoblots were reacted with mouse monoclonal anti-V5 antibody. Identical strains and fractions as in (A) were tested. The
migration of V5-tagged Msb2 and Pmt2 (strain CIS29) are indicated by the arrow and the triangle, respectively; a protein cross-reacting with the anti-
V5 antibody is marked by the asterisk. C. Secretion of HA-tagged Msb2 protein during growth on agar. Cell suspensions were dropped on a
membrane filter (pore diameter 0.45 mm) situated on a PVDF membrane, which had been placed on YPD agar (a). Colonies were allowed to grow for
15 h at 30uC (b). The membrane filter was removed and the PVDF membrane was probed by immunoblotting using rat anti-HA antibody (c). Strains
tested were (1) CAF2-1 (wild-type), (2) CIS23 (PMT1
HA), (3) ESCa3 (ACT1p-MSB2
HA-V5) and ESCa10 (MSB2p-MSB2
HA-V5). D. Gel filtration chromatography
of secreted Msb2. A Superdex 200 10/300 GL column was (a) calibrated using standard proteins of the indicated sizes (dotted lines) and (b) used to
fractionate 500 ml of the medium of strain ESCa3 (Msb2
HA-V5), which had been grown at 30uC in SD medium to OD600=10. The protein elution
profiles were recorded by absorption at 280 nm. 200 ml fractions were collected and (c) tested by immunoblotting for the presence of HA-tagged
Msb2. Fractions tested are placed at a position corresponding to the elution profile in b). E. Glycosylation of secreted Msb2. (a) Growth medium of
strain ESCa3 (Msb2
HA-V5) was not treated (1) or treated with b-elimination reagent mixture over night (2,3); the sample in lane 3 was heated to 80uC
before reagent addition in an attempt to increase deglycosylation. (b) The medium was not treated (1) or treated with TFMS (2). Samples were tested
by immunoblotting as in A. The migration of glyosylated and deglycosylated Msb2* are indicated by the filled and open arrows, respectively. (c) Msb2
secreted by pmt mutants defective in protein-O-mannosyltransferases carrying carried pES11a (Msb2
HA-V5). Strains included ESca18 (pmt1), ESCa19
(PMT2/pmt2), ESCa20 (pmt4), ESCa21 (pmt5) and ESCa22 (pmt6) and were tested by immunblotting as in A.
doi:10.1371/journal.ppat.1002501.g002
Figure 3. Activity of Msb2 variants. A. Structure of Msb2 protein variants. The positions of signal sequence (SS), transmembrane region (TM) and
HA- and V5-epitope tags are indicated. Plasmids encoding variants were chromosomally integrated into strain FCCa28, which produces the inactive
Msb2-D1 variant by the msb2D1 allele. Resulting transformants (encoded variants) were strains ESCa3 (Msb2
HA-V5), ESCa25 (Msb2-DN), ESCa38 (Msb2-
DC) and ESCa39 (Msb2-DTM-C). Corresponding phenotypes are summarized in the table and are presented in Figure S1. +, wild-type phenotype; 2,
msb2 mutant phenotype with regard to Msb2* release, hypha formation, caspofungin resistance (Cas
R) and Cek1 phosphorylation (Cek1-P). B. Cek1
activation by strains producing variant Msb2 proteins. Cells were grown to stationary phase (st), diluted in fresh YPD medium, grown to OD600=0.8 at
37uC and incubated further for 1 h in the presence (+) or absence (2) of tunicamycin (2 mg/ml). Cells in stationary phase (st) and after 1 h incubation
were harvested and assayed for the activation of MAPK Cek1 by immunoblottings; the Hog1 MAPK protein signal was used as the loading control.
Strains as in A., in addition strains ESCa37 encoding the Msb2-tail variant and strain ESCa7 carrying an empty vector (control) were tested.
doi:10.1371/journal.ppat.1002501.g003
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brane region (variant Msb2-DTM-C) or solely the 108 cytoplasmic
variant Msb2 tail residues were as defective for Msb2 phenotypes
as mutants REP18 carrying a complete deletion of the MSB2 ORF
or strain FCCa27 only producing N-terminal residues 1–406 of
Msb2 (Msb2-D1). Inactivity of the Msb2-DTM-C variant was not
caused by lack of protein biosynthesis since amounts of Msb2*
released into the medium were comparable for all HA-tagged
variants (Figure S1). However, with regard to the activation of
Cek1 a particular phenotype of these deletion variants was
observed. The wild-type strain ESCa3 showed low levels of
phosphorylation in stationary phase and phosphorylation was
increased during logarithmic growth, which was stimulated further
in the presence of tunicamycin [9] (Figure 3 B). In contrast, strain
ESCa25 producing the Msb2-DN variant activated Cek1 not only
in stationary phase but also in the absence of tunicamycin to high
levels. In addition, strain ESCa38 carrying the Msb2-DC variant
was impaired in its ability to activate Cek1 in response to
tunicamycin. Strains producing the Msb2-DTM-C and the Msb2-
tail were completely unable to activate Cek1 phosphorylation.
Thus, it appears that the Msb2 N-terminal, transmembrane and
cytoplasmic domains region convey different functions in Cek1
phosphorylation.
C. albicans msb2 are supersensitive to LL-37
C. albicans ESCa3 expressing ACT1p-MSB2
HA-V5 released
considerable amounts of the Msb2* glycoprotein into the complex
YPD growth medium, amounting to 76 mg/ml and 150 mg/ml in
logarithmic growth (OD600=1) and in stationary phase
(OD600=6). Msb2* was quantitated immunologically by a dot-
blot procedure, because its high glycosylation status prevented
quantitation by standard methods. We considered that this
glycoprotein could contribute to defense against immunological
responses of the human host, in particular to the attack by AMPs
[20]. To verify this concept we first tested if the presence of Msb2
would contribute to basal levels of AMP resistance of C. albicans.
Wild-type strains were significantly more LL-37-resistant than
msb2 mutants (Figure 4 A). Sensitivity of a msb2 sho1 double mutant
was only slightly increased compared to a msb2D1 single mutant
and a sho1 single mutant showed wild-type resistance indicating
that Msb2 but not Sho1 mediates LL-37 resistance. The increased
LL-37 sensitivity of msb2 mutant strains versus a wild-type strain
was also correlated with increased fluorescent staining of mutant
cells [26,27] by TAMRA-labelled LL-37 (Figure 4 B). We also
observed that in the presence of LL-37 the msb2 mutant tended to
aggregate more readily than wild-type cells [31].
We next tested the LL-37 sensitivity of the above series of
transformants producing truncated Msb2 variants. Interestingly,
while the transformant only synthesizing the C-terminal tail of
Msb2 was as sensitive as the msb2D1 mutant all other
transformants showed wild-type sensitivity (Figure 4 C). Even the
transformant producing Msb2 deleted for its transmembrane
region and C-tail was not supersensitive, although as described
above this Msb2 variant was inactive in complementing msb2
mutant phenotypes (Figure 3). It was concluded that the basal
resistance of C. albicans to LL-37 depended on the secreted
extracellular domain of Msb2 but its N-terminal domain was not
required for this action. Since full-length and N-terminally deleted
Msb2* are O-glycosylated to a large part by Pmt1 (Figure 2)
transformants were constructed producing doubly tagged Msb2 in
C. albicans strains defective in each of the 5 Pmt proteins (a
heterozygous strain was used in case of PMT2 because of its
essentiality for growth). Among these transformants only the pmt1
mutant was LL-37 supersensitive supporting the notion that Pmt1-
directed O-glycosylation of Msb2* is required to provide resistance
to LL-37.
In conclusion, these results suggest that the secreted extracel-
lular Msb2* domain is required for LL-37 basal resistance of C.
albicans.
Secreted Msb2 protects against AMPs
Several mechanisms are possible to explain the requirements of
Msb2 (and Sho1) for LL-37 resistance and one mechanism is
inactivation of LL-37 by the secreted Msb2
*. To verify this concept
we first purified Msb2* fragment from the growth medium by
affinity chromatography using anti-HA antibody and verified that
the purified material consisted solely of the heterogeneous
.460 kDa protein by silver staining and immunoblotting
(Figure 5 A). Next we asked if the purified Msb2* would
proteolytically attack cathelicidin LL-37. Msb2
* and AMPs were
co-incubated and then assayed AMPs on a 18% SDS-PAGE gel
(which excludes Msb2
*). Msb2
* co-incubation did not diminish
amounts of LL-37 and no degradation products were observed
(Figure 5 B) even if a 22.5% SDS-PAGE gel was used (data not
shown). Furthermore, long term incubations (16 h) of Msb2*
preparations with substrates of a protease detection kit able to
detect a wide variety of protease did not detect any protease
activity (data not shown). Therefore, it was concluded that Msb2*
preparations had no general proteolytic activity. In additional pre-
tests we bound Msb2* (or Msb2-DN*) to wells of microtiter dishes
and checked if TAMRA-labelled LL-37 would absorb to these
wells. Msb2* coating did indeed stimulate binding of LL-37-
TAMRA significantly, while preincubation with unlabelled LL-37
reduced subsequent binding (Figure 5 C). This result indicates that
LL-37 has a specific binding site on Msb2*.
To test a potential function of Msb2* in AMP protection we set
up an AMP activity assay, in which we treated C. albicans for 1.5 h
with AMPs in the absence or presence of purified Msb2
* and then
assessed fungal viability by determination of colony-forming units
(CFU). The results show that added Msb2
* rescued C. albicans from
LL-37 killing, which was obvious for the wild-type strain and even
more significant for msb2 and msb2 sho1 mutants; even an E.coli
strain was protected against LL-37 by Msb2* (Figure 5 D).
Interestingly, even the shortened Msb2*-DN fragment secreted
and purified from strain ESCa25 was able to provide protection,
although a concentration dependence of its activity revealed that it
is slightly less active in AMP inactivation compared to the full-
length Msb2
* protein (Figure 5 E). AMP inactivating activity was
Figure 4. Msb2 synthesis protects C. albicans against LL-37. A. Basal LL-37-resistance of C. albicans depends on Msb2. The indicated strains
were incubated with different LL-37 amounts for 1.5 h at 37uC before plating of cells to determine colony-forming units (CFUs). Standard deviations
of triplicate measurements are indicated; statistical differences of mutant versus control strain cfu values were evaluated by a t-test. B. Staining of
C. albicans by TAMRA-labelled LL-37. 50 ml of cells were resuspended in PBS were incubated for 5 min with 5 mg LL-37-TAMRA before visualization
using phase contrast and fluorescence microscopy. CAF2-1. +/+; FCCa27, 2/2; ESCa3, 2/2[+]. C, D. LL-37 sensitivity of C. albicans strains producing
Msb2 variants (C) and of pmt mutants producing undeleted Msb2 (D). Transformants producing variant Msb2 proteins are described in Figures 2 and
3. Strain suspensions (5 ml) were co-incubated with 2 mg LL-37 for 1.5 h before CFU determination. Means and standard deviations of triplicate assays
are shown. Statistical significance using a t-test is indicated by * (p,0.05), ** (p,0.01) and *** (p,0.001).
doi:10.1371/journal.ppat.1002501.g004
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PLoS Pathogens | www.plospathogens.org 8 February 2012 | Volume 8 | Issue 2 | e1002501also detected by merely using medium (secretome) of a C. albicans
wild-type strain (CAF2-1) for co-incubation with LL-37 (Figure 5
F). As expected, medium of the msb2D1 strain (FCCa27) had no
protective effect, while medium of the pmt1 mutant (SPCa2) had
reduced inactivating activity.
These findings demonstrate that the extracellular Msb2 domain
has an additional function in C. albicans biology, e. g. in LL-37
defense, which is different from its roles in cell wall integrity and
filamentation.
Secreted Msb2 protects C. albicans against histatin-5
C. albicans is known to be sensitive to low levels of histatin-5 [23–
26,32,33]. We considered the possibility that higher Msb2
* levels
occurring in the vicinity of C. albicans colonies in the human host
could protect against histatin-5 as we had found for LL-37.
Although we did not observe a significant higher sensitivity to
histatin-5 in msb2 mutants (as for LL-37) we found that added
purified Msb2
* did indeed protect C. albicans strains significantly
against histatin-5 (Figure 6). As expected, HA peptide used for
elution of Msb2* from the anti-HA antibody in affinity
chromatography did not provide protection. The protective action
of Msb2
* was not restricted to C. albicans because even an E. coli
strain was rescued from histatin-5 killing (Figure 6). Thus, we
conclude that protection by the secreted Msb2 glycofragment is
not specific for LL-37 but extends to other AMPs including
histatin-5 and affects microorganisms other than C. albicans.
Figure 5. Msb2*-mediates protection of C. albicans and E. coli against LL-37. A. Purification of Msb2*. Msb2* in culture medium of strain ESCa3
(lanes1,3)was affinity-purifiedusingananti-HAcolumn(lanes2,4)andsampleswereseparatedbySDS-PAGE(4–20%acrylamidegel).For silverstaining
50 ml of medium/purified (med/pur) fractions (lanes 1, 2) andfor immunoblotting using an anti-HA antibody 15 ml of medium/purified fractions (lanes 3,
4) was analyzed. B. Msb2 does not degrade LL-37. 3 mg of LL-37 were co-incubated without (lane 1) or with 10 mg of Msb2* (lane 2) for 1.5 h at 37uC.
Samples were separated on a 18% SDS-PAGE gel; the migration of standard proteins is indicated. C. Immobilized Msb2* binds LL-37. 10 mg Msb2* or
Msb2-DN* were allowed to attach to each well of polystyrene microtiter plates over night at 4uC. Wells were washed with PBST and unspecific binding
sites were removed by incubation with skim milk solution. 5 ml( 5mg) of TAMRA-labelled LL-37 was allowed to bind for 1 h, wells were washed and
TAMRA emission was recorded at 590 nm. As a control, coated wells were incubated first with 3 mg of unlabelled LL-37 for 1 h before addition of LL-37-
TAMRA. D. Msb2*-mediated protection of C. albicans and E. coli against LL-37. Strain suspensions (5 ml) were co-incubated with LL-37 in the absence or
presence of 10 mg Msb2* or 10 mg of its deleted variant Msb2*-DN for 1.5 h before determination of viable cell counts (CFUs). As a control, 10 mg BSA
was used to replace Msb2*. C. albicans strains CAF2-1 (wt), FCCa27 (msb2D1), REP21 (msb2D0 sho1) and E. coli DH5aF9 were tested; means and standard
deviations of triplicate assays are shown. E. Msb2* concentration dependence. C. albicans strain CAF2-1 was incubated with 3 mg LL-37 in the absence
and presence of the indicated amounts of purified Msb2* and the deleted Msb2*-DN variant. In addition, the activity of HA peptides used for affinity
purificationofMsb2*wastested.F.ProtectionofC.albicansagainstLL-37bymediumproteins(secretome).3 mgLL-37was addedtocellsofstrainCAF2-
1( 5ml; OD600=0.3) in the absence or presence of culture medium (17 ml) of C. albicans strains grown to stationary phase. Following incubation for 1.5 h
at 37uC cell viability (CFU) was tested. Secretome of control strain CAF2-1, FCCa27 (msb2D1) and SPCa2 (pmt1) was used. Means and standard deviations
of triplicate assays are shown. Statistical significance was evaluated using a t-test (*, p,0.05; **, p,0.01; ***; p,0.001).
doi:10.1371/journal.ppat.1002501.g005
Figure 6. Msb2*-mediates protection of C. albicans and E. coli against histatin-5. C. albicans strains CAF2-1 (wt), FCCa27 (msb2D1), REP18
(msb2D0) and E. coli DH5aF9 were allowed to react with the indicated amounts of histatin-5 for 1.5 h at 37uC, in the absence or presence of the
affinity-purified secreted Msb2* protein. Colony-forming units were determined on YPD (C. albicans strains) or on LB medium (E. coli).
doi:10.1371/journal.ppat.1002501.g006
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A complex interplay of responses and counter-responses
characterizes the encounter of microbial pathogens with the
human host. Opportunistic pathogens including C. albicans may be
commensals, held in check by the immune system and supported
by actions of the pathogen that favour a commensal life-style
[1,34]. Conversely, immunological impairment or other conditions
can favour propagation of pathogens and result in disease through
microbial virulence traits and/or immune hyperstimulation
causing autoimmune damage [35] Immune cells detect surface
structures of C. albicans including glucan and mannoproteins and
trigger IL-17-dependent reactions [2,3] including the production
of AMPs, which kill the pathogen and attract immune cells
[19,20]. The C. albicans protein Msb2 has a dual function to
stabilize the fungal cell wall and we show here that it is also
required to block an important aspect of the immune response by
inactivating AMPs (Figure 7).
Fungal pathogens have a relatively high ability to resist attack by
hydrolytic enzymes or small toxic molecules including antifungals
in the human host. Cell wall damage is restored or compensated
for by signaling pathways that sense the defect and initiate
appropriate rescue responses [6]. In C. albicans defects in glucan or
chitin are sensed especially by pathways containing the Mkc1 or
Hog1 MAP kinases that trigger enhanced glucan or chitin
biosynthesis [7,36]. Defects in protein glycosylation are transmit-
ted mainly via the Cek1 MAP kinase pathway and lead to
activation of individual isoforms of protein-O-mannosyltrans-
ferases [9,10]. Blockage of N-glycosylation by tunicamycin
depends on Cek1 and upregulates PMT1 transcription, while
inhibition of Pmt1-O-glycosylation stimulates transcription of
PMT2 and PMT4 genes. Interestingly, we found that the Msb2
membrane sensor protein functioning at the head of the Cek1
pathway is itself a highly glycosylated protein as in other fungal
species. Despite the presence of 5 potential acceptor sites no
evidence for N-glycosylation of Msb2 was obtained but the
secreted Msb2 migrated faster in a pmt1 mutant (not in other
homozygous pmt mutants) indicating that Pmt1 is partially
responsible for Msb2 O-mannosylation. Residual O-chains in a
pmt1 strain were removed by chemical treatment suggesting that
they are contributed by the Pmt2 isoform, which is essential for
growth [27]. Lack of Pmt1 glycosylation was previously shown to
increase phosphorylation of Cek1 and to activate PMT2/4
transcription [9,10] and we add here that lack of the N-terminal
Msb2 glycodomain leads to constitutive Cek1 phosphorylation.
Conceptually, lack of Msb2 O-glycosylation could trigger Cek1
phosphorylation but other O-glycosylated proteins interacting with
Msb2 could also provide the triggering signal. Signaling by
proteins interacting with Msb2 is suggested by the finding that
tunicamycin-treatment induces Cek1 phosphorylation, although
Msb2 does not appear to be N-glycosylated itself. In S. cerevisiae,
however, Msb2 is N-glycosylated and O-mannosylated by the
Pmt1, 2 and 4 isoforms; furthermore, activation of the Cek1
homolog Kss1 occurred only in cells lacking Pmt4 and inhibited
for N-glycosylation by tunicamycin [37,38]. Thus, Msb2 glycosyl-
ation and resulting MAP kinase activation proceed differently in C.
albicans and S. cerevisiae.
The single transmembrane region of Msb2 divides the protein
in a large glycosylated extracellular and a small cytoplasmic
domain in C. albicans, S. cerevisiae and other fungi. A S. cerevisiae
Msb2-GFP fusion has been shown to get efficiently cleaved
leading to release of the extracellular domain into the medium
[17]. This processing occurs at a yet undefined site and requires
the Yps1 yapsin-type protease suggesting that it is directly or
indirectly involved in the cleavage. Similarly, using doubly
epitope-tagged Msb2 we found that in C. albicans Msb2 is cleaved
almost quantitatively, which sheds the extracellular domain into
the medium and retains the cytoplasmic domain in the cells.
However, in C. albicans the closest homologs of ScYps1, Sap9,
Sap10 [29], and serine endoproteinase Kex2 [30] were not
required for CaMsb2 processing. Cleavage/release was found to
occur both in liquid and on surfaces and the amount of secreted
Msb2 depended on the number of growing C. albicans cells. Thus,
importantly, the level of released Msb2 is a measure of C. albicans
propagation. In agreement, Msb2 peptides were recently
identified in the secretome of C. albicans yeast and hyphal
cultures; peptides corresponded to the extracellular domain
including residue 1290 upstream of the transmembrane region
[39].
Figure 7. Model for Msb2 functions. The dual function of C. albicans Msb2 protein is shown. The precursor protein (A) is cleaved during growth
and the extracellular domain, which is highly O-glycosylated (indicated by white dots), is shed into the medium (B). Msb2 has an intracellular function
in activating the Cek1 MAP kinase and the secreted exodomain is able to protect cells against AMPs (triangles).
doi:10.1371/journal.ppat.1002501.g007
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and Cek1 phosphorylation was studied using C. albicans strains
producing Msb2 variants. A large deletion of 450 N-terminal
residues adjacent to the signal sequence (Msb2-DN) led to
functional Msb2 able to complement defects of the msb2 mutant;
this variant differed from the native protein, however, in that the
Cek1 MAP kinase was constitutively phosphorylated. In agree-
ment, S. cerevisiae Msb2 deletions of the extracellular domain have
been found to hyperactivate the dedicated MAP kinase Kss1 [17].
Different phenotypes were obtained for C-terminal deletions of C.
albicans Msb2. While a Msb2 variant deleted for its C-terminal end
and the transmembrane region (Msb2-DTM-C) was completely
inactive, a deletion retaining the transmembrane region (Msb2-
DC) was fully functional in complementing msb2 phenotypes.
Unexpectedly, however, the latter variant did not respond to
tunicamycin-treatment by induction of Cek1 phosphorylation, in
agreement with results obtained for a similar S. cerevisiae Msb2
variant [38]. We conclude that the transmembrane region of Msb2
is absolutely required for Msb2 functions and furthermore, that
tunicamycin-regulated signaling to the Cek1 MAP kinase requires
the cytoplasmic domain. Conceivably, the cytoplasmic domain
could be directly involved in regulation of Cek1 kinase activity or it
could participate in gene regulation as has been reported for
signaling mucins and the Notch protein in higher eukaryotes
[18,40].
In the human host C. albicans contacts surfaces of body cells
including immune cells, which may phagocytose the pathogen and
elicit a wave of antifungal activities. Resident or induced soluble
defense molecules such as immunoglobulins, complement factors
and AMPs kill or block the growth of the pathogen. AMPs have a
wide range of antiviral, antibacterial and antifungal activities and
provide an antimicrobial barrier on mucosal surfaces such as
histatins produced and secreted by salivary glands or they are
components of the antimicrobial armory of neutrophils that
produce cathelicidins (LL-37) and defensins [20]. Furthermore,
AMPs act as chemoattractants recruiting leukocytes to sites of
infection [19,21]. C. albicans is known to be sensitive to histatins,
LL-37 and defensins, which inhibit fungal growth by cytoplasmic
membrane disruption, interference with mitochondrial activity or
yet undefined mechanisms [23–26]. Furthermore, binding of LL-
37 or histatins to cell wall carbohydrates prevents adhesion of C.
albicans to host cells and plastic surfaces [31]. It should be noted
also that bacterially-produced AMPs such as the lantibiotic nisin
secreted by Lactobacillus lactis contribute to the diversity and high
concentration of AMPs in the human body [41]. Nevertheless, a
myriad of microbial commensals including some opportunistic
pathogens persist as cohabitants because they are at least partially
AMP-resistant. Several AMP-resistance mechanisms have been
reported. Cleavage of AMPs by soluble or membrane-bound
proteases has been described for many bacterial species and it has
been shown that C. albicans is also able to cleave histatin-5 by the
yapsin-type protease Sap9 [42,43]. Another evasion mechanism
known in bacteria is the secretion of AMP-binding proteins that
act as decoys deflecting AMPs from their dedicated action at
microbial cell surfaces. Examples include the secreted SIC,
staphylokinase and FAF proteins by Streptococcus pyogenes, Staphylo-
coccus aureus and the commensal Finegoldia magna, respectively [44–
46]. Here we describe that an analogous mechanism is relevant
also for fungal pathogens since shedding of a large glycosylated
fragment of the Msb2 sensor protein renders C. albicans AMP-
resistant. Msb2 shedding reached high levels during liquid growth
(about 150 mg/ml in stationary phase) and was also observed
during surface growth. Purified Msb2 fragment effectively blocked
the fungicidal activity of histatin-5 and LL-37 even at a .20 fold
molar excess of AMPs suggesting multiple binding sites. Interest-
ingly, a C. albicans msb2 mutant was supersensitive to LL-37 but not
to histatin-5 suggesting that the relatively small amount of cell-
associated Msb2 suffices to protect against LL-37 but not against
histatin-5. This finding agrees with the recent finding that LL-37
but not histatin-5 binds to C. albicans cell-wall carbohydrates [31].
The underlying molecular mechanisms for AMP binding to Msb2*
remain to be determined. We found that the Pmt1-type of O-
mannosylation is partially required for Msb2 glycosylation, its
binding to LL-37 and for LL-37 resistance of wild-type cells, which
raises the question if the glycostructures of Msb2* directly or
indirectly affect LL-37 binding. Previous work has established the
binding of LL-37 to various glycostructures including bacterial
lipopolysaccaride [47], bacterial exopolysaccharides [48], human
glycosaminoglycans [49] and fungal cell-wall polysaccharides [31].
These glycostructures may provide anionic contact sites for
cationic AMPs such as LL-37 and histatin-5, which are enriched
for basic amino acids (net charge +6 and, respectively, +12 at
physiological pH). Since O-mannosyl side chains of Msb2* do not
add net charge (unless they carry as yet undefined modifications)
they do not allow ionic interactions with cationic AMPs, although
non-ionic interactions cannot be excluded. Possibly, the functional
role of O-mannosylation is indirect by providing an extended,
bottle-brush conformation of the protein, as it is often observed in
highly O-glycosylated protein domains [50]; this conformation
could help to expose carboxylate side groups of aspartate and
glutamate residues in Msb2* that could interact with basic residues
of AMPs. Other C. albicans components including members of the
Hog1 MAP kinase pathway are also involved in basal AMP
resistance [51]; since Msb2 is not an upstream element in the
Hog1 pathway of C. albicans [52] it probably regulates AMP
resistance independently of Hog1. In a process that is analogous to
functions of Msb2, the Pra1 protein of C. albicans is partially shed
and impairs immune responses, in this case by binding of human
factor H in solution leading to downregulation of the complement
system in the vicinity of fungal cells [53].
We reported previously that in the standard mouse model of
systemic infection (tail vein injection) no significant attenuation of
virulence was detected for a msb2 mutant [9]. However, the
systemic infection model may not appropriately reflect growth of
C. albicans in the form of biofilms or foci of infection within organs,
which are expected to be surrounded by a diffusion cloud of shed
Msb2 at high levels that cause quorum resistance depending on
fungal cell numbers. Shedding of Msb2 may also be important for
C. albicans commensal growth, e. g. survival in the gut, where it is
confronted with AMPs of other microbial commensals such as
nisin produced by Lactobacillus [41]. On the other hand, shed Msb2
is able to provide cross-protection for other species as we have
shown for protection of E. coli against LL-37 and histatin-5.
Therefore, we propose that novel models for virulence and
commensalism are needed to test the biological relevance of Msb2
and its shedding. Shed Msb2 may be of diagnostic value since its
levels reflect fungal growth in the human host. Shed Msb2 is
highly soluble and proteolytically stable because of its extensive
glycosyl modifications and its presence in body fluids may be
indicative of hidden localized fungal infections.
Materials and Methods
Strains and media
C. albicans strains are listed in Table 1. In C. albicans strain
REP18 the MSB2 ORF of both alleles is completely removed [9];
this msb2 mutant allele is referred to as msb2D0. Strain FCCa27/28
contains partially deleted alleles designated msb2D1 (encoding the
Msb2 Shedding
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the URA-blaster method. A 3.8 kb genomic fragment encom-
passing MSB2 was PCR-amplified using primers IPF6003-NotI and
IPF6003-SacII and cloned into pUK21 (NotI, SacII). The large
BamHI-KpnI fragment of the resulting plasmid was ligated to the
hisG-URA3-hisG blaster cassette of p5921 to generate pUK-




FCCa27 as CAI4 but msb2D1::hisG/msb2D1::hisG-URA3-hisG this study
FCCa28 as CAI4 but msb2D1::hisG/msb2D1::hisG this study
REP3 ura3D::imm434/ura3D::imm434 his1D::hisG/his1D::hisG sho1::FRT/sho1::FRT [9]
REP18 ura3D::imm434/ura3D::imm434 his1D::hisG/his1D::hisG msb2D0::FRT/msb2D0::FRT [9]
REP21 ura3D::imm434/ura3D:imm434 his1D::hisG/his1D::hisG sho1::hisG/sho1::hisG-URA3-hisG msb2D0::FRT/
msb2D0::FRT
[9]
CAP1-3121 as CAI4 but pmt1D::hisG/pmt1D::hisG [27]
SPCa2 as CAP1-3121, but ura3D::imm434/ URA3 [27]
P2-22 as CAI4 but PMT2/pmt2D::hisG [27]
CAP4-2161 as CAI4 but pmt4D::hisG/pmt4D::hisG [27]
P5-5711 as CAI4 but pmt5D::hisG /pmt5D::hisG [27]
CAP2-2311 as CAI4 but pmt6D::hisG/pmt6D::hisG [27]
CNA4 as CAI4 but kex2::hisG/kex2::hisG [56]
Dsap9 as CAI4 but sap9::hisG/sap9::hisG [29]
Dsap10 as CAI4 but sap10::hisG/sap10::hisG [29]
Dsap9 Dsap10 as CAI4 but sap9::hisG/sap9::hisG sap10::hisG/sap10::hisG [29]
CIS23 as CAI4 but PMT1/PMT1
HA::SAT1 Schmidt and Ernst, unpublished
CIS29 as CAI4 but PMT2/PMT2
V5::URA3 Schmidt and Ernst, unpublished
ESCa3 (21,2,3) as FCCa28 but LEU2/LEU2::pES11a (ACT1p-MSB2
HA-V5) this study
ESCa5 (21,2,3) as FCCa28 but LEU2/LEU2::pES11c (ACT1p-MSB2
HA-V5 end) this study
ESCa7 (21,2,3) as FCCa28 but LEU2/LEU2::pDS1044-2 (ACT1p) this study
ESCa8 (21,2,3) as FCCa28 but LEU2/LEU2::pES10 (ACT1p-MSB2
HA) this study
ESCa9 (21,2,3) as FCCa28 but msb2D1/msb2D1::pES10 (MSB2p-MSB2
HA) this study
ESCa10 (21,2,3) as FCCa28 but msb2D1/msb2D1::pES11a (MSB2p-MSB2
HA-V5) this study
ESCa11 (21,2,3) as FCCa28 but msb2D1/msb2D1::pES11c (MSB2p-MSB2
HA-V5 end) this study
ESCa18 (21,2,3) as CAP1-3121 but LEU2/LEU2::pES11a (ACT1p-MSB2
HA-V5) this study
ESCa19 (21,2,3) as P2-22 but LEU2/LEU2::pES11a (ACT1p-MSB2
HA-V5) this study
ESCa20 (21,2,3) as CAP4-2164 but LEU2/LEU2::pES11a (ACT1p-MSB2
HA-V5) this study
ESCa21 (21,2,3) as P5-5744 but LEU2/LEU2::pES11a (ACT1p-MSB2
HA-V5) this study
ESCa22 (21,2,3) as CAP2-2311 but LEU2/LEU2::pES11a (ACT1p-MSB2
HA-V5) this study
ESCa25 (21,2,3) as FCCa28 but LEU2/LEU2::pES14 (ACT1p-MSB2-DN
HA-V5) this study
ESCa26 (21,2,3) as CAP1-3121 but LEU2/LEU2::pES14 (ACT1p-MSB2-DN
HA-V5) this study
ESCa27 (21,2,3) as P2-22 but LEU2/LEU2::pES14 (ACT1p-MSB2-DN
HA-V5) this study
ESCa28 (21,2,3) as CAP4-2164 but LEU2/LEU2::pES14 (ACT1p-MSB2-DN
HA-V5) this study
ESCa29 (21,2,3) as P5-5744 but LEU2/LEU2::pES14 (ACT1p-MSB2-DN
HA-V5) this study
ESCa30 (21,2,3) as CAP2-2311 but LEU2/LEU2::pES14 (ACT1p-MSB2-DN
HA-V5) this study
ESCa33 (21,2,3) as Dsap9 but LEU2/LEU2::pES11a (ACT1p-MSB2
HA-V5) this study
ESCa34 (21,2,3) as Dsap10 but LEU2/LEU2::pES11a (ACT1p-MSB2
HA-V5) this study
ESCa35 (21,2,3) as Dsap9 Dsap10 but LEU2/LEU2::pES11a (ACT1p-MSB2
HA-V5) this study
ESCa36 (21,2,3) as CNA4 but LEU2/LEU2::pES11a (ACT1p-MSB2
HA-V5) this study
ESCa37 (21,2,3) as FCCa28 but LEU2/LEU2::pES15 (PCK1p-MSB2-tail) this study
ESCa38 (21,2,3) as FCCa28 but LEU2/LEU2::pES16 (ACT1p-MSB2-DC
HA) this study




PLoS Pathogens | www.plospathogens.org 12 February 2012 | Volume 8 | Issue 2 | e10025016003.ko.Urab. The NotI-SacII disruption cassette of this plasmid
was used according to the standard URA blaster protocol to
partially delete both MSB2 alleles in C. albicans CAI4 generating
FCCa27 (Ura
+) and FCCa28 (Ura
2). Strain FCCa28 allows
integration of MSB2 expression vectors in the MSB2 locus by
transformation with HpaI-cleaved plasmid and ectopically in LEU2
after digestion with EcoRV, which place MSB2 alleles under
transcriptional control of the MSB2 and ACT1 promoter,
respectively. The disruption was verified by colony PCR using
primers IPF6003-3verif/ i-p2-Ura3ver and by Southern blottings
(data not shown). E. coli strain DH5aF9 was used for plasmid
constructions and for AMP protection experiments.
Strains were grown on/in standard YPD or SD media. Pmt1-
inhibitor OGT2599 was resuspended in DMSO to prepare a stock
solution of 10 mM [54]. Standard drop dilution tests (10 fold
dilutions to 10
25) were used to determine sensitivity to inhibitors.
Hyphal formation was induced by growth at 37uC on YPM
medium containing 2% mannitol as sole carbon source or in liquid
YP medium containing 10% serum [27].
MSB2 expression vectors
Relevant restriction site used for the construction of MSB2
variant alleles are shown in Figure 1A. A MSB2 allele encoding
heme agglutinin (HA)-tagged Msb2 was constructed by first PCR-
amplifying the 59-end of the MSB2 coding region using primers
Msb2-ATG-XhoI and IPF6003-39 (all oligonucleotides are listed in
Table S1). The PCR fragment contained a novel XhoI site
upstream of the ATG and extended to bp position 3227 of the
ORF, 50 bp downstream of the PstI site. The XhoI-PstI subclone in
pUC21 was mutagenized using the Quikchange kit (Stratagene)
and primers HA-hin and HA-her were used to insert the sequence
encoding a single HA epitope (11 amino acids) 1500 bp
downstream of the ATG start codon sequence. The 39-end of
the MSB2 ORF was then amplified by genomic PCR using
primers Msb2-int2 und Msb2-Stopp-XhoI-NotI, which generated a
fragment containing a MSB2 sequence from 61 bp upstream of the
PstI site to the XhoI site downstream of the stop codon sequence
that was generated in the PCR reaction. This 39 PCR fragment
was mixed with the above 59 XhoI-PstI fragment and the full-length
modified MSB2 allele was generated by overlap PCR using the
flanking primers Msb2-ATG-XhoI und Msb2-Stopp-XhoI-NotI.
The resulting XhoI fragment was cloned downstream of the
ACT1 promoter in C. albicans expression vector pDS1044-1 to
generate plasmid pES10.
To insert the V5 epitope-encoding sequence into MSB2 a 1037-
bp region from upstream of the PstI site to the middle of
cytoplasmic domain sequence was PCR amplified using pES10 as
template and primers PCR1 Hin und PCR1 Mitte Her, the latter
primer added V5 sequences to the PCR product. In addition, a
second PCR fragment (712 bp) was generated by PCR using
primers PCR2 Mitte Hin (containing the V5 sequence) und PCR2
Her (downstream of the ApaI site in the 39-UTR). Because both
fragments contained the V5 sequence an overlap PCR using
flanking primers PCR1 Hin und PCR2 Her generated a 1695 bp
PCR fragment that was cut with NheI and ApaI and then inserted
into pES10 to replace the corresponding unmodified fragment.
The resulting expression plasmid encoding the MSB2
HA-V5 allele
was designated pES11a. In a similar approach, an expression
vector encoding a Msb2 variant carrying the V5 epitope at the C-
terminal end of Msb2 was constructed using primers PCR1 Hin,
PCR1 Ende Her, PCR2 Ende Hin and PCR2 Her; the resulting
plasmid was designated pES11c (MSB2
HA-V5 end).
Expression vectors encoding Msb2 variants were constructed by
primer-directed mutagenesis of plasmid pES11a, using the
Quikchange kit (Stratagene). Plasmid pES14 encoding Msb2-DN
lacking residues 33–481 of Msb2 was constructed using primers
Cla1 Del1 next1/-2, plasmid ES16 encoding the Msb2-DC variant
lacking the cytoplasmic tail of Msb2 was constructed using
oligonucleotides MSB2 Stopp nach TM Hin/-Her and plasmid
ES17 encoding the Msb2-DTM-C variant lacking transmembrane
region and cytoplasmic tail was constructed using oligonucleotides
MSB2 Stopp vor TM Hin/-Her. Plasmid ES15 encoding the
Msb2-tail variant was constructed by PCR-amplification of
sequences encoding the cytoplasmic tail by primers C-Tail vor/
-ru ¨ck and inserting it into downstream of the PCK1 promoter in
plasmid pBI-1. Plasmids were integrated into the LEU2 locus of
strain FCCa28 as described above.
Protein methods
Strains were grown in 50 ml YPD or SD medium at 30uCt o
OD600=6–10 and cells were harvested by centrifugation. Cells
were washed with water and resuspended in lysis buffer (50 mM
HEPES/pH 7.5; 150 mM NaCl; 5 mM EDTA; 1% Triton X-
100) containing protease inhibitors (Complete, Mini, Roche). Cells
were broken by shaking with glass beads at 4uC for 2610 min on a
vibrax (Janke & Kunkel, 2200 rpm) or with a FastPrep
homogenizer (MP Biochemicals). Cell debris and glass beads were
separated from the crude cell extract by centrifugation. For
immunoblottings proteins were separated by SDS-PAGE (8%,
18% or 4–20% acrylamide) and blotted to PVDF membranes.
Protein standards used were the PageRuler set (Fermentas; 11–
170 kDa) or the HiMark set (Invitrogen; 31–460 kDa) of proteins.
Membranes were probed using rat anti-HA monoclonal antibody
(1:2000; Roche) or mouse monoclonal anti-V5 antibody (1:2000;
Serotec) and visualized using peroxidase-coupled goat anti-rat or
anti-mouse antibodies (1:10000; Thermo) and the SuperSignal
West Dura chemiluminescent substrate (Pierce).
Gel filtration chromatography was done on a Superdex 200 10/
300 GL column (GE healthcare) equilibrated with SD medium.
Elution characteristics were established using a set of standard
proteins (Sigma) containing carboanhydrase (23 kDa), BSA
(66 kDa), ADH (150 kDa), b-amylase (200 kDa), apoferritin
(434 kDa) and thyroglobulin (669 kDa); the void volume (V0) was
determined using Blue dextran (2000 kDa). Protein elution volumes
(Ve) were monitored at 280 nm and fractions were collected by an
A ¨KTA prime plus (GE Healthcare) at a flow speed of 0.4 ml/min.
To determine the molecular mass of secreted Msb2, strain ESCa3
(Msb2
HA-V5) was grown in SD medium to OD600=10. Cells were
removed by centrifugation and 500 ml of the medium was degassed,
sterile-filtered and applied to the Superdex column. 200 ml fractions
were collected and 20 ml per fraction were tested for the presence of
Msb2
HA by immunoblotting. The approximate molecular mass of
Msb2
HA was calculated from the standard protein graph using the
equation y=62258e23,695x (x: Ve/Vo; y: molecular mass).
Deglycosylation reactions using PNGase F and a-mannosidase
(jack bean) were carried out according to the instructions of the
manufacturers (Roche; Sigma). To remove O-glycosylation the
GlycoProfile b-elimination kit (Sigma) was used, either without or
with pretreatment of the sample at 80uC. 200 ml of the ESCa3
growth medium was acetone-precipitated and resuspended in the
same volume of water. 40 ml of the reagent mixture was added and
the sample was incubated over night at 4uC. The sample was
neutralized with HCl and 20 ml were analyzed by immunoblot-
ting. The GlycoProfile IV kit (Sigma) was used to remove all forms
of protein glycosylation by trifluoromethanesulfonic acid (TFMS).
1.5 ml of the growth medium of strain ESCa3 was lyophilized and
150 ml of TFMS was added and the proteins incubated at 4uC for
25 min. 4 ml of 0.2% bromophenol blue was added and
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monitored by the yellowish coloring. This latter step was carried
out in a bath of dry ice in ethanol. Reagents in the samples were
removed by dialysis against PBS using Slide-A-Lyzer cassettes
(Thermo).
The secreted Msb2
HA domain was purified by affinity
chromatography from cultures grown in SD medium containing
2% casamino acids to an OD600=10 using a column (1 ml)
containing agarose beads covalently coupled to 3.5 mg of
monoclonal anti-HA high affinity antibody (Roche). The column
equilibrated with buffer (20 mM Tris/HCl, pH 7.5; 0.1 M NaCl;
0.1 mM EDTA) and 50–400 ml of the culture medium containing
Msb2
HA were loaded and the column was washed with 20 bed
volumes of wash buffer (20 mM TrisHCl/pH 7.5; 0.1 M NaCl;
0.1 mM EDTA; 0,05% Tween 20). The Msb2
HA protein was
eluted twice by 1 ml (1 mg) of HA peptide (Roche) in Tris-
buffered saline.
Proteins on SDS-PAGE gels were routinely visualized by
Coomassie blue or silver staining and protein concentrations were
determined by the Bradford assay using a commercial assay kit
(BioRad). Because of the high glycosylation status of Msb2* its
concentration could not be determined reliably by any of these
methods. Therefore, we developed a dot blot procedure, in which
known molar concentrations of HA peptide were compared to
Msb2* (or Msb2-DN*) signals resulting from reaction with the
anti-HA antibody. Dilutions of a HA peptide solution (Roche)
were spotted on an activated PDVF membrane and a dilution
series of the sample containing unknown amounts of Msb2* was
spotted alongside. The membrane was processed as for immuno-
blottings and the resulting signals were recorded using a Fujifilm
LAS400 mini image analyzer and evaluated with the Fujifilm
Multi Gauge program. The standard curve derived from the HA
peptide were used to calculate molar amounts of the Msb2*
sample.
Msb2* samples were assayed for protease contamination using
the Protease Detection Kit (Jena Bioscience) that detects a wide
variety of proteases, including serine proteases, cysteine proteases
and acid proteases. Substrate solution (50 ml) and incubation
buffer (50 ml) were mixed with 100 ml (50 mg) of Msb2* in TBS
and incubated at 37uC for 16 h. 120 ml precipitation reagent was
added and samples were incubated at 37uC for 30 min. Tubes
were centrifuged at 12.0006 g for 5 min and 50 ml of the
supernatant was transferred to a flat bottom 96 well plate, 150 ml
assay buffer was added and absorbance at 492 nm was measured
using a plate spectrophotometer (Biotek).
MAPK activation assay
Strains were grown over night to stationary phase in YPD
medium and diluted into YPD medium to an OD600=0.1. Cells
were grown to OD600=0.8 at 37uC and incubated further for 1 h
in the presence (+) or absence (2) of tunicamycin (2 mg/ml).
Immunoblots were prepared as described previously verifying
equal loading by Ponceau red staining of the membranes [9]. Blots
were probed with anti-phospho-p44/42 MAP kinase (Cell
Signaling Technology) to detect phosphorylated Cek1 protein
and ScHog1 polyclonal antibody (Santa Cruz Biotechnology) was
used to detect all forms of Hog1 [9].
Antimicrobial peptide assays
Over night cultures of C. albicans and E. coli DH5aF9 were
diluted and grown in YPD at 30uCt oa nO D 600=0.3. Cells were
harvested by centrifugation and washed with and resuspended in
PBS. Triplicate assays containing 5 ml cell suspension and 0–10 mg
LL-37 (Sigma) or histatin-5 (AnaSpec Inc.) in a total volume 25 ml
were incubated 1.5 h at 37uC, diluted 500 fold and plated on
YPD. Colony forming units were determined after 2 d of growth
at 30uC. The action of LL-37 on cells was visualized by
fluorescence microscopy using LL-37-TAMRA (Innovagen).
To assay binding of LL-37 to Msb2* a microtiter plate assay was
used. 10 mg Msb2* or Msb2-DN* in 200 ml PBS were allowed to
bind wells of a 96 well flat bottom polystyrene plate over night at
4uC. The wells were washed three times with PBST (PBS
containing 0.05% Tween 20). Then 200 ml of blocking buffer
(5% w/v nonfat dry milk in PBST) was added for 2 hours at room
temperature. Wells were washed three times and incubated with
5 mg LL-37 5-TAMRA for one hour. After washing three times,
the fluorescence was measured on a Tecan infinite 200 plate
reader (excitation 560 nm, emission wavelength 590 nm). In a
competition experiment, following Msb2* binding, 3 mg LL-37
was added to wells and incubated for one hour before cells were
washed and LL-37-TAMRA was added.
Supporting Information
Figure S1 Phenotypes of C. albicans strains producing deleted
Msb2 variants. A. Antifungal sensitivity. Sensitivities of strains to
caspofungin (125 ng/ml) and tunicamycin (2 mg/ml) were tested
by a drop dilution test on YPD agar. B. Hypha formation.
Colonies of strains were photographed following growth for 2 d at
37uC on YPM agar. C. Detection of Msb2* in the growth
medium. Strains were grown in YPD medium to OD600=6,
centrifuged and the medium (20 ml) was analyzed by immuno-
blotting using rat anti-HA antibody. Strains included CAF2-1 (wt),
ESCa3 (Msb2
HA-V5), ESCa25 (Msb2-DN), ESCa37 (Msb2-tail),
ESCa37 (Msb2-DC), ESCa39 (Msb2-DTM-C) and control strains
FCCa27/28 (Msb2-D1) and CAP4-2164 (pmt4). The following pmt
mutant strains carrying plasmid pES14 encoding the Msb2-DN
variant were also tested by immunoblotting: ESca26 (pmt1),
ESCa27 (PMT2/pmt2), ESCa28 (pmt4), ESCa29 (pmt5) and
ESCa30 (pmt6).
(PDF)
Table S1 List of oligonucleotides.
(PDF)
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